JPM: Takeda acquires Ariad in $5.2B deal

Takeda has been on the hunt for acquisition targets in the U.S. Ariad fits the bill, but comes with perhaps unwanted scrutiny over the price tag for its main drug. 

By Jacob Bell • Jan. 9, 2017

Novartis hooks up with Ionis for access to CV drugs

Novartis now has the option to boost its cardiometabolic offerings in a deal that could be worth more than $1.6 billion.

By Suzanne Elvidge • Jan. 9, 2017

JPM: Illumina links up with IBM's Watson

The partnership aims to speed the analysis and interpretation of sequencing data created by one of Illumina's tumor profiling panels. 

By Suzanne Elvidge • Jan. 9, 2017

JPM: Ipsen snatches up Merrimack's Onivyde for $575M

Selling its crown jewel, Merrimack will substantially cut its workforce and pivot from commercialization efforts to a new focus on three pipeline assets. 

By Ned Pagliarulo • Jan. 8, 2017

Prescribed Reading: Quiet before the storm

M&A was slow in 2016 and 2017 is off to a slow start. But the JP Morgan conference in San Francisco next week could put dealmaking back in full swing. 

By Lisa LaMotta • Jan. 6, 2017

Tiny startup hooks Takeda in celiac deal

PvP Biologics will get some much-needed cash to fund preclinical work on a therapeutic for celiac disease. 

By Suzanne Elvidge • Jan. 5, 2017

Diet no more: Arena sheds Belviq in Eisai sale

The beleaguered biotech will no longer be weighed down by its failing weight loss drug, getting much-needed cash in a divestment. 

By Lisa LaMotta • Jan. 5, 2017

AstraZeneca taps APT in latest deal

An antithrombotic deal plugs a gap in AstraZeneca's CV pipeline.

By Suzanne Elvidge • Jan. 5, 2017

Is Gilead poised for deal-making?

The big biotech has made a new hire that could mean it is looking to expand its oncology presence in a big way. 

By Lisa LaMotta • Jan. 4, 2017

Tiny Rana makes a play for mRNA with Shire deal

Shire sold rights to its messenger RNA platform in exchange for an equity stake in Cambridge-based Rana Therapeutics. 

By Ned Pagliarulo • Jan. 4, 2017

RedHill, Concordia team up to market IBS drug

Under terms of a new agreement, RedHill will gain some U.S. promotional rights to Concordia's Donnatal.

By Jacob Bell • Jan. 3, 2017

7 takeover targets to look out for in 2017

After a slow 2016, industry followers expect at least a slight uptick in M&A next year as a new president, patent losses and promising markets entice further deals.

By Jacob Bell • Jan. 3, 2017

Report: Positive outlook for big pharma in 2017

At least one analyst believes there will be more catalysts in R&D and an uptick in M&A during the coming year. 

By Lisa LaMotta • Dec. 27, 2016

Prescribed Reading: An uptick in year-end M&A

Several companies are striking deals to round out the year, while others are trying to bury bad data, and the FDA cracks down on manufacturing. 

By Lisa LaMotta • Dec. 23, 2016

Novartis, Sun Pharma enter deal for oncology drug Odomzo

Approved in 2015, Odomzo hasn't been much of a revenue earner for Novartis but should help Sun expand its oncology offerings. 

By Jacob Bell • Dec. 23, 2016

Catalyst picks up manufacturing rights to hemophilia drug

The deal gives the U.S. biotech full cGMP manufacturing for clinical trials for the rare bleeding disorder. 

By Suzanne Elvidge • Dec. 22, 2016

Sygnis puts cash to use, acquires C.B.S. Scientific

The German company has expanded this year, also completing a takeover of proteomics device maker Expedeon back in September.

By Jacob Bell • Dec. 22, 2016

Japanese pharma snaps up cancer biotech Tolero

The acquisition expands Sumitomo Dainippon Pharma's pipeline in oncology and hematology. 

By Suzanne Elvidge • Dec. 22, 2016

Novartis buttresses Alcon with Encore Vision takeover

Helping to deliver on a promise made at the onset of 2016, Novartis plans to strengthen its Alcon business through an acquisition of Encore Vision.

By Jacob Bell • Dec. 21, 2016

Novartis sells US rights to 3 COPD drugs

Sunovion Pharmaceuticals will take over U.S. commercialization, although Novartis will continue to manufacture the medicines. 

By Jacob Bell • Dec. 21, 2016

Incyte puts up $200M in bispecifics deal with Merus

The collaboration will cover up to 11 bispecific antibody programs and could substantially expand Incyte's pipeline.

By Ned Pagliarulo • Dec. 21, 2016

Akebia partners with Otsuka on anemia drug

The Japanese co Otsuka will pay $125 million upfront, with another $140 million in committed funds tied to global development of vadadustat. 

By Suzanne Elvidge • Dec. 21, 2016

Allergan picks up regenerative med company for $2.9B

Since Allergan sold its generics business to Teva, CEO Brent Saunders has stayed true to his "stepping stone" dealmaking strategy. 

By Ned Pagliarulo • Dec. 20, 2016

Conatus soars on Novartis deal

The Swiss pharma put up $50 million to gain access to Conatus' experimental NASH drug, joining a growing list of biopharmas investing in the space.

By Ned Pagliarulo • Dec. 20, 2016

Bristol continues immuno-oncology push in deal with PsiOxus

The deal could be worth more than $930 million, and gives Bristol-Myers exclusive rights to a pre-clinical oncolytic virus therapy.

By Jacob Bell • Dec. 20, 2016